Welcome to our dedicated page for LAVA Therapeutics N.V. SEC filings (Ticker: LVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding LVTX’s science-heavy disclosures shouldn’t require a PhD. Every LAVA Therapeutics SEC filing packs dense clinical data on its Gammabody® bispecific T-cell engagers, R&D spending, and cash runway—details critical for judging immuno-oncology risk.
Our AI-powered platform turns those complex Form 20-F pages—and the 6-K updates that follow each trial milestone—into concise insights you can act on. Whether you search for “lava therapeutics insider trading Form 4 transactions” or “lava therapeutics quarterly earnings report 10-Q filing,” you’ll land here and find:
- Real-time Form 4 insider transactions with alerts that flag executive stock moves moments after they hit EDGAR.
- Plain-English breakdowns of annual reports—think “lava therapeutics annual report 10-K simplified”—highlighting pipeline progress, collaboration revenue, and cash burn projections.
- Side-by-side comparisons of each 6-K (8-K material events explained) so you can track dose-escalation data, FDA feedback, or new licensing deals without reading the full PDF.
Common questions are answered along the way: Where is LVTX’s proxy statement executive compensation? How do I read a lava therapeutics earnings report filing analysis? What does that shelf registration mean for dilution? Our AI extracts the numbers, footnotes, and trial endpoints that matter—saving hours while boosting confidence.
Stop searching multiple sources. Get every filing type—from S-8 share plans to F-3 offerings—plus “understanding lava therapeutics SEC documents with AI” tutorials, all updated in real time. When fresh data shapes the future of gamma-delta T-cell therapy, you’ll see it here first.
LAVA Therapeutics N.V. has effectively been acquired by XOMA Royalty Corporation through a completed tender offer and is transitioning off the public markets. Buyer agreed to purchase all common shares at $1.04 per share plus one contingent value right (CVR), which may provide additional cash payments under a separate CVR agreement. The offer, as extended, expired on November 12, 2025, with 22,877,463 shares (about 87% of shares) validly tendered and accepted for payment.
A subsequent offering period through November 20, 2025 brought total tenders to 23,956,708 shares, about 91.1% of shares outstanding, including 1,079,245 shares tendered during this later window. Trading in LAVA’s shares on Nasdaq was suspended prior to the market opening on November 21, 2025, and Nasdaq filed a Form 25 to remove the listing. The company plans to end its SEC reporting obligations by filing a Form 15 on or about December 1, 2025. Effective November 21, 2025, Stephen Hurly and Fred Powell ceased to be executive officers, with severance terms referenced from LAVA’s prior proxy statement.
LAVA Therapeutics (LVTX) reported the completion of XOMA Royalty Corporation’s tender offer and post-offer reorganization. As of the subsequent closing date, a total of 23,956,708 common shares, representing approximately 91.1% of LAVA’s outstanding shares, were validly tendered and accepted for payment, including 1,079,245 shares (about 4.2%) tendered during the subsequent offering period. The shares ceased trading on Nasdaq prior to the opening on November 21, 2025, and Nasdaq will file a Form 25 to delist and deregister the shares. LAVA and XOMA plan to file Form 15 to terminate registration and suspend LAVA’s reporting obligations, completing LAVA’s transition to a non-reporting, privately held company structure.
LAVA Therapeutics N.V. (LVTX) reported an insider equity transaction by its Chief Financial Officer. On 11/13/2025, the CFO disposed of 65,000 common shares and had 124,700 share options cancelled. Both actions were carried out under a Purchase Agreement between LAVA Therapeutics and XOMA Royalty Corporation.
Each common share was exchanged for $1.04 in cash plus one non-transferable contingent value right (CVR). Each in-the-money option was cancelled in return for cash, based on the excess of $1.04 over the option’s exercise price, and one CVR per underlying share, net of applicable taxes and deductions.
LAVA Therapeutics N.V. reported that a director cancelled an option to buy 33,390 common shares with an exercise price of $0.93 per share on 11/13/2025. The option had been scheduled to expire on 02/12/2035. Under a Purchase Agreement between the company and XOMA Royalty Corporation, the cancellation consideration consists of cash equal to the excess of $1.04 over the per-share exercise price multiplied by the number of shares underlying the option, plus one contingent value right for each in-the-money share. Following this transaction, the reporting person held 0 derivative securities of this type.
LAVA Therapeutics N.V. (LVTX)33,390 common shares with a per share exercise price of $0.93 on 11/13/2025. The option had been exercisable until 02/12/2035. According to a purchase agreement dated 08/03/2025 between the company and XOMA Royalty Corporation, the option was cancelled in exchange for cash and contingent value rights (CVRs). The cash component equals the excess of $1.04 over the option’s exercise price multiplied by the number of underlying shares, plus one CVR for each share underlying the in-the-money option.
LAVA Therapeutics N.V. (LVTX) reported a Form 4 showing that a director’s stock option was fully cancelled in a structured transaction. On 11/13/2025, a share option covering 33,390 common shares with a per share exercise price of $0.93 was disposed of as a derivative security.
The option was cancelled under a Purchase Agreement between LAVA Therapeutics and XOMA Royalty Corporation. In exchange, the reporting person received cash and contingent value rights (CVRs) equal to the excess of $1.04 over the option exercise price, multiplied by the number of underlying shares, plus one CVR for each in-the-money underlying share. Following this transaction, the reporting person reported 0 derivative securities beneficially owned.
LAVA Therapeutics N.V. (LVTX) disclosed on a Form 4 that one of its directors reported the cancellation of a stock option on 11/13/2025. The derivative position was a right to buy common shares at an exercise price of $0.93 per share covering 33,390 underlying common shares, and following the transaction the director held zero of these derivative securities directly.
The filing explains that this option was cancelled under an August 3, 2025 Purchase Agreement between the issuer and XOMA Royalty Corporation. In exchange, the option holder became entitled to cash and contingent value rights, calculated as the excess of $1.04 over the option’s exercise price multiplied by the number of underlying shares, plus one contingent value right for each in-the-money option share.
A director of LAVA Therapeutics N.V. (LVTX) reported a change in holdings on Form 4. On 11/13/2025, a stock option covering 33,390 common shares with a per share exercise price of $0.93 was cancelled. The option was cancelled under a Purchase Agreement between the issuer and XOMA Royalty Corporation. In exchange, the holder became entitled to cash and contingent value rights, calculated as the excess of $1.04 over the option’s exercise price multiplied by the number of underlying shares, plus one CVR for each in-the-money underlying share.
LAVA Therapeutics N.V. director reported a disposition of common shares and related options tied to a Purchase Agreement with XOMA Royalty Corporation. The director disposed of 10,000 common shares on 11/13/2025 and no common shares remained beneficially owned afterward. A stock option covering 33,390 common shares with a per share exercise price of
LAVA Therapeutics N.V. director reported changes in holdings tied to a previously signed Purchase Agreement with XOMA Royalty Corporation. On 11/13/2025, the director disposed of 30,000 common shares, receiving $1.04 in cash per share plus one contingent value right (CVR) for each share. On the same date, a stock option covering 33,390 common shares with a $0.93 exercise price was cancelled under the same agreement in exchange for cash and CVRs, calculated as the excess of $1.04 over the option exercise price multiplied by the number of underlying shares, plus one CVR per in-the-money share.
FAQ
What is the current stock price of LAVA Therapeutics N.V. (LVTX)?
What is the market cap of LAVA Therapeutics N.V. (LVTX)?
